Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises BenevolentAI on $90M Investment from Temasek

October 15, 2019

LONDONCovington has advised BenevolentAI on its $90 million investment from Temasek, a Singapore-headquartered investment company.

BenevolentAI aims to improve the lives of patients suffering from diseases with no effective treatment. The Benevolent Platform® is used by scientists and technologists to find new ways to treat disease, improve the efficacy, and lower the development time and costs of new treatments. 

The funding will be used to scale and further develop the Benevolent Platform for drug discovery and development. BenevolentAI will continue to advance its growing pipeline of internal drug development programmes and collaborations with strategic partners across its key therapeutic areas.

The Covington team was led by Simon Amies (corporate) and included Camilla Rogers (corporate), Denitsa Marinova (corporate) and Guy Dingley (tax and incentives).


Share this article: